---
title: 'Vice President, Medical Affairs – Hematology-Oncology at Nurix'
canonical: 'https://feeny.ai/job/vice-president-medical-affairs-hematology-oncology-nurix-brisbane-6dhxvcxp04yx'
type: 'job'
last_seen: '2026-09-09'
---

# Vice President, Medical Affairs – Hematology-Oncology at Nurix

- **Company:** Nurix
- **Location:** Brisbane, CA
- **Posted:** 2026-06-08
- **Last confirmed live:** 2026-09-09
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8582375002

## Job description

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

Position Overview

Nurix Therapeutics is seeking a Vice President, Medical Affairs, Hematology-Oncology to build, expand, and lead a best-in-class Medical Affairs organization supporting the company’s transition from a clinical-stage biotechnology company toward commercialization as its hematology-oncology portfolio advances into late-stage clinical development.

This executive will provide strategic and operational leadership across the full Medical Affairs function, including medical strategy, ﬁeld medical, scientiﬁc communications, evidence generation, thought leader engagement, medical information, and launch readiness. The role will play a central role in shaping the scientiﬁc and medical strategy for Nurix’s targeted protein degradation portfolio and helping deﬁne the company’s external scientiﬁc leadership in hematologic malignancies.

The role will be a key cross-functional partner to Clinical Development, Commercial, Market Access, Regulatory, Legal, and Compliance as Nurix plans and executes future commercialization activities. This leader will contribute broadly to portfolio strategy, lifecycle planning, and enterprise-level decision making as a member of the senior leadership team.

## Responsibilities

- Lead and scale the Medical Affairs function to support the progression of Nurix’s hematology-oncology programs into late-stage clinical development and future commercial readiness.
- Own the overall Medical Affairs strategy for the hematology-oncology portfolio, ensuring alignment with development plans, portfolio priorities, and corporate objectives.
- Lead development of the scientiﬁc platform and differentiated medical narrative for Nurix hematology-oncology programs within rapidly evolving treatment landscapes.
- Partner closely with Clinical Development to shape late-stage medical strategy, including data generation priorities, scientiﬁc narrative, external engagement plans, and lifecycle opportunities.
- Develop and execute integrated medical plans across ﬁeld medical, scientiﬁc communications, publications, medical education, medical information, insight gathering, and evidence generation.
- Expand and lead a high-performing MSL organization focused on credible scientiﬁc exchange, compliant insight capture, and strong engagement with key external experts, investigators, and treatment centers.
- Lead external engagement in hematologic malignancies, including advisory boards, investigator relationships, disease-area thought leader engagement, and interactions with cooperative groups and broader scientiﬁc communities.
- Serve as a senior medical representative of the company with external experts, investigators, and scientiﬁc leaders, helping establish Nurix as a credible scientiﬁc leader in hematologic malignancies and targeted protein degradation.
- Direct publication and scientiﬁc communication strategy for key clinical data, congress presentations, medical content, symposia, and educational initiatives.
- Lead integrated evidence generation strategies spanning registrational support, post-marketing evidence development, real-world evidence, health economics and outcomes research, treatment sequencing, and product differentiation opportunities.
- Partner with Commercial and Market Access to ensure medical strategy informs launch readiness, access planning, scientiﬁc platform development, training initiatives, and broader commercialization strategy.
- Monitor the external hematology-oncology landscape, including standard-of-care evolution, competitor data, treatment guidelines, and emerging scientiﬁc trends, and translate insights into actionable medical strategy.
- Ensure all Medical Affairs activities are conducted in compliance with applicable legal, regulatory, and company standards.
- Provide medical and scientiﬁc leadership to executive governance discussions related to portfolio prioritization, lifecycle strategy, label expansion opportunities, external partnerships, and commercialization readiness.
- Support global Medical Affairs planning and coordination, including scientiﬁc congress strategy, evidence generation activities, and external engagement initiatives across key regions.

Qualiﬁcations

- MD, PhD, DO, or PharmD required; oncology/hematology experience
- 15+ years of biopharmaceutical Medical Affairs experience with signiﬁcant leadership responsibility, including direct accountability for launch and post-approval
- Demonstrated leadership experience supporting late-stage development and commercialization of hematology-oncology therapies, including launch planning, scientiﬁc positioning, and post-approval medical strategy.
- Demonstrated expertise in evidence generation (Phase 3b/4, RWE, HEOR), scientiﬁc communications, MSL leadership, and cross-functional launch planning.
- Strong understanding of global and US. regulatory, compliance, and payer environments related to medical activities and drug promotion.
- Experience in highly innovative therapeutic platforms, ﬁrst-in-class mechanisms, or rapidly evolving treatment landscapes strongly preferred.
- Excellent leadership, communication, and collaboration skills, with the ability to operate strategically while remaining hands-on in a fast-moving pre-commercial and launch environment.
- Demonstrated ability to build and scale high-performing Medical Affairs organizations in emerging biotechnology or growth-stage commercial settings preferred.

Salary Range:  $348,000 - $399,000

Fit with Nurix Culture and Values

- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Associate Director, electronic Quality Management System (eQMS)](https://feeny.ai/job/associate-director-electronic-quality-management-system-eqms-nurix-brisbane-k35rdgj6th4k) — Brisbane, CA
- [Director, Nonclinical Toxicology Operations](https://feeny.ai/job/director-nonclinical-toxicology-operations-nurix-brisbane-california-a7ynjr847xvh) — Brisbane California, United States
- [Director, Medical Affairs - Immunology](https://feeny.ai/job/director-medical-affairs-immunology-nurix-brisbane-california-8q3w67dea5xq) — Brisbane California, United States
- [Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-strategy-hematology-zsgdf1qycbew) — Brisbane California, United States
- [Senior Administrative Assistant, R&ED](https://feeny.ai/job/senior-administrative-assistant-r-ed-nurix-brisbane-california-9k9rhmyvd955) — Brisbane California, United States
- [Senior Director, Quality Control](https://feeny.ai/job/senior-director-quality-control-nurix-brisbane-california-d4hqe06vb3t7) — Brisbane California, United States
- [Associate Director, Chemical Engineering](https://feeny.ai/job/associate-director-chemical-engineering-nurix-brisbane-california-6gbpc8ben8eh) — Brisbane California, United States
- [Senior Analyst, FP&A](https://feeny.ai/job/senior-analyst-fp-a-nurix-brisbane-california-g7qxkkvsfwbf) — Brisbane California, United States
- [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-wkgs5dx1e7eq) — Brisbane California, United States
- [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-57ydhjmqgfm6) — Brisbane California, United States